AOH1996

A novel small molecule inhibitor targeting PCNA

AOH1996
INN
Drug class
Routes of administration
Pregnancy category
Bioavailability
Metabolism
Elimination half-life
Excretion
Legal status
CAS Number
PubChem
DrugBank
ChemSpider
KEGG

AOH1996 is a small molecule inhibitor that targets the proliferating cell nuclear antigen (PCNA), a protein that plays a critical role in DNA replication and DNA repair processes. This compound has been studied for its potential use in cancer therapy, as it can disrupt the function of PCNA, thereby inhibiting the proliferation of cancer cells.

Mechanism of Action

AOH1996 functions by binding to PCNA, which is a key component of the DNA replication fork. PCNA acts as a sliding clamp that encircles DNA, providing a platform for the recruitment of various proteins involved in DNA synthesis and repair. By inhibiting PCNA, AOH1996 interferes with the replication machinery, leading to the stalling of DNA replication and the induction of apoptosis in rapidly dividing cells, such as cancer cells.

Potential Applications

The primary application of AOH1996 is in the field of oncology. Due to its ability to selectively target cancer cells, it is being investigated as a therapeutic agent for various types of cancer, including breast cancer, lung cancer, and prostate cancer. The specificity of AOH1996 for cancer cells over normal cells is attributed to the higher dependency of cancer cells on PCNA for their rapid proliferation.

Research and Development

Research on AOH1996 is ongoing, with studies focusing on its efficacy, safety, and potential combination with other cancer therapies. Preclinical studies have shown promising results, and clinical trials are being designed to further evaluate its therapeutic potential.

Challenges and Considerations

While AOH1996 shows promise as a cancer therapeutic, there are challenges that need to be addressed. These include understanding the long-term effects of PCNA inhibition, potential resistance mechanisms that cancer cells might develop, and the optimization of dosing regimens to maximize efficacy while minimizing side effects.

Related pages

• Proliferating cell nuclear antigen
• DNA replication
• Cancer therapy
• Apoptosis